NDAOPHTHALMICDRUG-ELUTING CONTACT LENS
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
4
Data completeness
4/8 — Partial
ACUVUE THERAVISION WITH KETOTIFEN (ketotifen fumarate) by Johnson & Johnson is state, the lens when placed on the cornea, acts as a refracting medium to focus light rays on the retina to correct refractive ametropia for as long as the lens is worn (up to 24 hours while awake). First approved in 2022.
Drug data last refreshed 9h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACUVUE THERAVISION WITH KETOTIFEN is a drug-eluting contact lens that combines optical correction with ketotifen fumarate, a mast cell stabilizer and H1 receptor antagonist. It corrects refractive ametropia while preventing ocular allergic itch for up to 12 hours, allowing continued lens wear during allergen exposure. The lens acts as both a refracting medium and sustained-release delivery system for allergy relief.
Peak3.8 years to LOE
As a recently approved (2022) product in peak lifecycle with high competitive pressure (8/10), this brand is building market share and likely expanding its commercial team for field execution and market penetration.
Mechanism of Action
state, the lens when placed on the cornea, acts as a refracting medium to focus light rays on the retina to correct refractive ametropia for as long as the lens is worn (up to 24 hours while awake). Drug Component Ketotifen fumarate, a benzocycloheptathiophene derivative, is a H 1 receptor…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
Started Apr 2023
512 enrolled
Allergic Conjunctivitis
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
Started Nov 2022
229 enrolled
Seasonal Allergic Conjunctivitis
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
Started Oct 2022
188 enrolled
Allergic Conjunctivitis
A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle
Started Apr 2018
65 enrolled
Allergic Conjunctivitis
Worked on ACUVUE THERAVISION WITH KETOTIFEN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.